

according to Regulation (EC) No. 1907/2006

## Loratadine / Montelukast Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.4	09.04.2021	4579028-00005	Date of first issue: 08.07.2019
SECTION	1.1. Identification of	of the substance/mix	ture and of the company/undertaking
OLOHON			the company/undertaking
11 Drodu	at identifier		
1.1 Produ	ct identifier		
Trade	e name	: Loratadine / Mo	ntelukast Formulation
1.2 Releva	ant identified uses o	f the substance or mi	xture and uses advised against
			0

## Use of the Sub- : Pharmaceutical

stance/Mixture

#### 1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain
Telephone	:	44 1 670 59 30 00
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

### 1.4 Emergency telephone number

215-631-6999

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 Long-term (chronic) aquatic hazard, Category 2

H361f: Suspected of damaging fertility. H411: Toxic to aquatic life with long lasting effects.

### 2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)						
Hazard pictograms :						
Signal word :	Warning					
Hazard statements :	<ul><li>H361f Suspected of damaging fertility.</li><li>H411 Toxic to aquatic life with long lasting effects.</li></ul>					
Precautionary statements :	<ul> <li>Prevention:</li> <li>P201 Obtain special instructions before use.</li> <li>P273 Avoid release to the environment.</li> <li>P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.</li> </ul>					

according to Regulation (EC) No. 1907/2006



## Loratadine / Montelukast Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.4	09.04.2021	4579028-00005	Date of first issue: 08.07.2019

### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention. P391 Collect spillage.

Storage:

P405 Store locked up.

### Hazardous components which must be listed on the label:

Loratadine

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form combustible dust concentrations in air during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Montelukast	151767-02-1	Eye Irrit. 2; H319	>= 1 - < 10
Loratadine	79794-75-5	Repr. 2; H361f Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic	>= 3 - < 10
		aquatic toxicity): 1	

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice


: In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

according to Regulation (EC) No. 1907/2006



Version 1.4	Revision Date: 09.04.2021	-	9S Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019		
Prote	ction of first-aiders	:	and use the reco	lers should pay attention to self-protection, mmended personal protective equipment al for exposure exists (see section 8).		
lf inha	If inhaled			If inhaled, remove to fresh air. Get medical attention.		
In case of skin contact		:	In case of contact, immediately flush skin with soap and plen of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.			
In cas	se of eye contact	:	If in eyes, rinse v Get medical atte	vell with water. ntion if irritation develops and persists.		
lf swa	allowed	:	Get medical atte	NOT induce vomiting. ntion. roughly with water.		
<b>1.2 Most i</b> Risks	mportant symptoms a	nd e	ffects, both acut Suspected of da	-		
T I BIG			Contact with dus the skin.	t can cause mechanical irritation or drying of the eyes can lead to mechanical irritation.		
1.3 Indica	tion of any immediate	mec	lical attention an	d special treatment needed		
Treat	ment	:	Treat symptomation	tically and supportively.		
SECTION	N 5: Firefighting meas	sur	es			
5.1 Exting	uishing media					
-	<b>Juishing media</b> ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide ( Dry chemical			
Suita	ble extinguishing media	:	Alcohol-resistant Carbon dioxide (			
Suital Unsu media	ble extinguishing media itable extinguishing	:	Alcohol-resistant Carbon dioxide ( Dry chemical None known.	CO2)		
Suital Unsu media	ble extinguishing media itable extinguishing a al hazards arising from ific hazards during fire-	:	Alcohol-resistant Carbon dioxide ( Dry chemical None known.	CO2) <b>ixture</b> J dust; fine dust dispersed in air in sufficient and in the presence of an ignition source is a		





## Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021		DS Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019	
E 2 Adviso	for firefighters				
5.5 Advice	for firefighters				
Special protective equipment for firefighters		:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.		
Specif ods	Specific extinguishing meth- ods		cumstances and Use water spray f	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do	

### **SECTION 6: Accidental release measures**

## 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).	
6.2 Environmental precautions			
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.	
		с , , , , , , , , , , , , , , , , , , ,	es

### 6.3 Methods and material for containment and cleaning up

:

Methods for cleaning up	<ul> <li>Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal.</li> </ul>
	Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
	Dust deposits should not be allowed to accumulate on surfac- es, as these may form an explosive mixture if they are re-
	leased into the atmosphere in sufficient concentration.
	Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items
	employed in the cleanup of releases. You will need to deter-
	mine which regulations are applicable.
	Sections 13 and 15 of this SDS provide information regarding
	certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures

Static electricity may accumulate and ignite suspended dust causing an explosion.

Provide adequate precautions, such as electrical grounding

according to Regulation (EC) No. 1907/2006



# Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021	SDS Nu 4579028		Date of last issue: 10.10.2020 Date of first issue: 08.07.2019	
Adv	Local/Total ventilation Advice on safe handling Hygiene measures		and bonding, or inert atmospheres. Use only with adequate ventilation. Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safe practice, based on the results of the workplace exposure as sessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to t environment. If exposure to chemical is likely during typical use, provide e flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contar nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment appropriate degowning and decontamination procedures,		
7.2 Cond	ditions for safe storage,		of administra		
Req	uirements for storage as and containers	: Kee	o in properly	labelled containers. Store locked up. Store in the particular national regulations.	
Adv	ice on common storage		ot store with ng oxidizing a	the following product types: agents	
7.3 Spec	tific end use(s)				
-	cific use(s)	: No d	ata available		

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters


### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis		
Cellulose	9004-34-6 TW/ dust		10 mg/m3	GB EH40		
	dust)         Further information: For the purposes of these limits, respirable dust and inhalable dust are those fractions of airborne dust which will be collected when sampling is undertaken in accordance with the methods described in MDHS14/4 General methods for sampling and gravimetric analysis or respirable, thoracic and inhalable aerosols., The COSHH definition of a substance hazardous to health includes dust of any kind when present at a concentratio in air equal to or greater than 10 mg.m-3 8-hour TWA of inhalable dust or 4 mg.m-3 8-hour TWA of respirable dust. This means that any dust will be sub-					

according to Regulation (EC) No. 1907/2006



Version 1.4	Revision Date: 09.04.2021	SDS Number: 4579028-00005	Date of last issue: 10 Date of first issue: 08	
	have b the ap of size entry i depen fractio ble du and m respira to the materi	been assigned specific propriate limits., Most is. The behaviour, dep nto the human respira d on the nature and si ns for limit-setting purp st approximates to the outh during breathing atory tract. Respirable gas exchange region al are given in MDHS wn assigned WEL, all TWA (Respir	WELs and exposure to industrial dusts contain position and fate of any p tory system, and the boo ze of the particle. HSE of poses termed 'inhalable' fraction of airborne mat and is therefore available' dust approximates to th of the lung. Fuller definit 14/4., Where dusts conta the relevant limits should	dy response that it elicits, distinguishes two size and 'respirable'., Inhala- terial that enters the nose le for deposition in the e fraction that penetrates ions and explanatory ain components that have
	halable sampli MDHS ble, th hazarc in air e mg.m- ject to have b the ap of size entry i depen fractio ble du and m respira to the	e dust are those fractions ing is undertaken in action of 14/4 General method oracic and inhalable a dous to health includes equal to or greater that 3 8-hour TWA of resp COSHH if people are been assigned specific propriate limits., Most is. The behaviour, dep not the human respirated on the nature and si ns for limit-setting purp st approximates to the outh during breathing atory tract. Respirable gas exchange region	ons of airborne dust which cordance with the meth s for sampling and gravi erosols., The COSHH d s dust of any kind when n 10 mg.m-3 8-hour TW. irable dust. This means exposed to dust above wELs and exposure to industrial dusts contain position and fate of any p tory system, and the box ze of the particle. HSE of poses termed 'inhalable' a fraction of airborne mat and is therefore availab dust approximates to th of the lung. Fuller definit	metric analysis or respira- efinition of a substance present at a concentration A of inhalable dust or 4 that any dust will be sub- these levels. Some dusts these must comply with particles of a wide range particular particle after dy response that it elicits, distinguishes two size and 'respirable'., Inhala- terial that enters the nose le for deposition in the e fraction that penetrates
	their o	wn assigned WEL, all STEL (inhala dust)	the relevant limits shoul ble 20 mg/m3	d be complied with. GB EH40
	halable sampli MDHS ble, th hazard in air e mg.m- ject to have b the ap of size entry i depen fractio	e dust are those fractions ing is undertaken in action of 14/4 General method oracic and inhalable a dous to health includes equal to or greater that 3 8-hour TWA of resp COSHH if people are been assigned specific propriate limits., Most s. The behaviour, dep not the human respira d on the nature and sin ns for limit-setting purp	ons of airborne dust which cordance with the meth s for sampling and gravi erosols., The COSHH d s dust of any kind when n 10 mg.m-3 8-hour TW irable dust. This means exposed to dust above wELs and exposure to industrial dusts contain position and fate of any p tory system, and the boo ze of the particle. HSE of poses termed 'inhalable'	metric analysis or respira- efinition of a substance present at a concentration A of inhalable dust or 4 that any dust will be sub- these levels. Some dusts these must comply with particles of a wide range particular particle after dy response that it elicits,





## Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021			ate of last issue: 10.10.2020 ate of first issue: 08.07.2019	
	resp to th mat	biratory tra ne gas exc erial are gi	ct. Respirable dust a hange region of the iven in MDHS14/4.,	s therefore available for depo approximates to the fraction t lung. Fuller definitions and e Where dusts contain compor elevant limits should be comp	hat penetrates xplanatory nents that have
Monte	elukast 151 1	767-02-	TWA	40 µg/m3 (OEB 3)	Internal
			Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Lorata	adine 797	94-75-5	TWA	40 µg/m3 (OEB 3)	Internal
			Wipe limit	400 µg/100 cm <sup>2</sup>	Internal

#### 8.2 Exposure controls

#### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipm	t	
Eye protection	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty condi- mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there i potential for direct contact to the face with dusts, mists aerosols.	sa
Hand protection		
Material	Chemical-resistant gloves	
Remarks Skin and body protection	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon task being performed (e.g., sleevelets, apron, gauntlets posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove pote contaminated clothing.	s, dis- entially
Respiratory protection Filter type	If adequate local exhaust ventilation is not available or sure assessment demonstrates exposures outside the ommended guidelines, use respiratory protection. Equipment should conform to BS EN 143 Particulates type (P)	

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Appearance	: tablet
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available

according to Regulation (EC) No. 1907/2006



Vers 1.4	ion	Revision Date: 09.04.2021		S Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
	pН		:	No data available	9
	Melting	point/freezing point	:	No data available	9
		oiling point and boiling	:	No data available	9
	range Flash p	point	:	Not applicable	
	Evapor	ation rate	:	Not applicable	
	Flamm	ability (solid, gas)	:		stible dust concentrations in air during pro- g or other means.
	Flamm	ability (liquids)	:	Not applicable	
		explosion limit / Upper ability limit	:	No data available	9
		explosion limit / Lower ability limit	:	No data available	9
	Vapou	- pressure	:	Not applicable	
	Relativ	e vapour density	:	Not applicable	
	Relativ	e density	:	No data available	9
	Density	/	:	No data available	9
		er solubility n coefficient: n-	:	No data available Not applicable	9
		nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	Not applicable	
	Explos	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
9.2 (	Other ir	nformation			
	Molecu	llar weight	:	No data available	9
	Particle	e size	:	No data available	9

according to Regulation (EC) No. 1907/2006



Version 1.4	Revision Date: 09.04.2021		98 Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
SECTION	N 10: Stability and re	acti	vity	
<b>10.1 Reac</b> Not c	<b>tivity</b> lassified as a reactivity	haza	rd.	
	nical stability	na_a		
	e under normal conditio	ns.		
10.3 Poss	bibility of hazardous re	actio	ons	
Haza	rdous reactions	:	cessing, handl	pustible dust concentrations in air during pro ng or other means. strong oxidizing agents.
10.4 Cond	ditions to avoid			
Cond	itions to avoid	:	Heat, flames a Avoid dust forr	
	mpatible materials			
Mate	rials to avoid	:	Oxidizing agen	ts
	<b>mation on toxicologic</b> nation on likely routes c sure		f <b>ects</b> Inhalation Skin contact Ingestion	
			Eye contact	
Acut	e toxicity			
Not c	•			
	lassified based on avail	able	information.	
	•	able	information.	
Com	lassified based on avail	able	information.	
<u>Com</u> Mont	lassified based on avail ponents:		information. LD50 (Rat): > 5	,000 mg/kg
<u>Com</u> Mont	lassified based on avail ponents: elukast:			
<u>Com</u> Mont Acute	lassified based on avail ponents: elukast:		LD50 (Rat): > 5	> 5,000 mg/kg
Com Mont Acute	lassified based on avail ponents: relukast: e oral toxicity	÷	LD50 (Rat): > 5 LD50 (Mouse):	> 5,000 mg/kg ata available
Com Mont Acute Acute	lassified based on avail ponents: elukast: e oral toxicity e inhalation toxicity	÷	LD50 (Rat): > 5 LD50 (Mouse): Remarks: No da	> 5,000 mg/kg ata available
Com Mont Acute Acute Acute	lassified based on avail ponents: relukast: e oral toxicity e inhalation toxicity e dermal toxicity	÷	LD50 (Rat): > 5 LD50 (Mouse): Remarks: No da	> 5,000 mg/kg ata available ata available

according to Regulation (EC) No. 1907/2006



Version 1.4	Revision Date: 09.04.2021	SDS Number: 4579028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
		Assessment: tion toxicity	The substance or mixture has no acute inhala-
	corrosion/irritation	ailable information.	
<u>Com</u>	ponents:		
Mont	telukast:		
Spec Resu		: Rabbit : Mild skin irrit	ation
Lora	tadine:		
Spec Resu		: Rabbit : No skin irritat	ion
	ous eye damage/eye classified based on ava		
<u>Com</u>	ponents:		
Mont	telukast:		
Spec Resu		: Rabbit : Severe irritat	ion
Lora	tadine:		
Spec Resu		: Rabbit : No eye irritat	ion
Resp	biratory or skin sensi	tisation	
	sensitisation	ailable information.	
	<b>biratory sensitisation</b> classified based on ava		
<u>Com</u>	ponents:		
Mont	telukast:		
Rema	arks	: No data avai	able
Lora	tadine:		
Expo Spec	ssment	: Maximisation : Dermal : Guinea pig : Does not cau : negative	Test ise skin sensitisation.

according to Regulation (EC) No. 1907/2006



# Loratadine / Montelukast Formulation

Vers 1.4	sion	Revision Date: 09.04.2021		98 Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019			
	Germ cell mutagenicity Not classified based on available information.							
	Compo	onents:						
	Monte	lukast:						
	Genoto	oxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)			
					o mammalian cell gene mutation test nese hamster fibroblasts			
					nosomal aberration nese hamster ovary cells			
				Test Type: Alkalin Test system: rat h Result: negative				
	Genoto	oxicity in vivo	:	Test Type: Chrom Species: Mouse Cell type: Bone m Application Route Result: negative				
	Lorata	dine:						
		oxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)			
				Test Type: In vitro Result: negative	o mammalian cell gene mutation test			
				Test Type: Chrom Result: negative	nosome aberration test in vitro			
				Test Type: DNA c thesis in mammal Result: negative	lamage and repair, unscheduled DNA syn- ian cells (in vitro)			
	Genoto	oxicity in vivo	:	Test Type: Micror Species: Mouse Cell type: Bone m Application Route Result: negative	arrow			
	Germ o sessmo	cell mutagenicity- As- ent	:	Weight of evidenc	e does not support classification as a germ			

### Carcinogenicity


Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Versio 1.4	on	Revision Date: 09.04.2021		OS Number: 79028-00005	Date of last issue: Date of first issue:	
<u>c</u>	Compo	onents:				
S A E F		s tion Route ire time	:	Rat Oral 2 Years negative Mouse		
E		tion Route ire time	:	Oral 92 weeks negative		
S A L F S A E N	Exposu LOAEL Result Specie: Applica	s tion Route ure time s tion Route ure time		Rat Oral 2 Years 10 mg/kg body we positive Monkey Oral 17 Months 40 mg/kg body we negative		
S	Suspec	<b>Juctive toxicity</b> sted of damaging fertili pnents:	ity.			
	Montel Effects	ukast: on fertility	:	Result: Animal tes Test Type: Fertility Species: Rat, fem Application Route	e : Oral 800 mg/kg body we sting did not show a y ale : Oral 200 mg/kg body we	ny effects on fertility.
				Test Type: Fertility Species: Rat, fem Application Route Fertility: NOAEL: Symptoms: Reduc	ale : Oral 100 mg/kg body we	ight
	L <b>orata</b> Effects	dine: on fertility	:	Species: Rat, mal	е	

\_





# Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021		S Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
			Application Route: Fertility: LOAEL: 6 Result: Effects on	4 mg/kg body weight
Effects ment	on foetal develop-	:	Species: Rat Application Route: Developmental To Result: Embryo-fo	xicity: LOAEL: 48 mg/kg body weight
			Species: Rabbit Application Route: Developmental To Result: Embryo-fo	xicity: LOAEL: 48 mg/kg body weight
			Species: Rat Application Route: Developmental To	: Oral xicity: LOAEL: 12 mg/kg body weight
Reprod sessme	uctive toxicity - As- ent	:		adverse effects on sexual function and animal experiments.
<b>STOT</b>				

### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### **Components:**

Montelukast: Species NOAEL Application Route Exposure time Remarks	<ul> <li>Monkey, male and female</li> <li>150 - 300 mg/kg</li> <li>Oral</li> <li>53 Weeks</li> <li>No significant adverse effects were reported</li> </ul>
, pp. outon i to ato	: Rat 50 mg/kg : Oral : 53 Weeks : No significant adverse effects were reported
Species NOAEL Application Route Exposure time Remarks	<ul> <li>Mouse</li> <li>50 mg/kg</li> <li>Oral</li> <li>14 Weeks</li> <li>No significant adverse effects were reported</li> </ul>
<b>Loratadine:</b> Species NOAEL	: Rat : 4 mg/kg

according to Regulation (EC) No. 1907/2006



# Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021	SDS Number: 4579028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
Expos	ation Route sure time t Organs	: 8 mg/kg : Oral : 180 Days : Central nervou : Effects are of li	s system mited toxicological significance.
Expos	EL L cation Route sure time t Organs	<ul> <li>Monkey</li> <li>0.4 mg/kg</li> <li>4 mg/kg</li> <li>Oral</li> <li>180 Days</li> <li>Central nervou</li> <li>Effects are of lit</li> </ul>	s system mited toxicological significance.
Not cl	ation toxicity assified based on avai		
-	rience with human ex ponents:	posure	
Skin d	elukast: contact ontact tion		
Lorat Ingest	adine:	: Symptoms: Fa	tigue, Headache, dry mouth, Nausea
	I 12: Ecological info		

**Components:** 

### Montelukast:

mernerender		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
		EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

according to Regulation (EC) No. 1907/2006



Version 1.4	Revision Date: 09.04.2021	-	9S Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
			mg/l Exposure time: 72 Method: OECD Te Remarks: No toxic	
Toxicity	to microorganisms	:	Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
Toxicity icity)	to fish (Chronic tox-	:	Method: OECD Te	2 d Iles promelas (fathead minnow)
	to daphnia and other invertebrates (Chron- ty)	:		d magna (Water flea) city at the limit of solubility
Loratad	line:			
Toxicity		:	LC50 (Lepomis m Exposure time: 96 Method: OECD Te	
	to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxicity plants	to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te	
			NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
M-Facto icity)	or (Acute aquatic tox-	:	1	
Toxicity	to microorganisms	:	EC50 : > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition

according to Regulation (EC) No. 1907/2006



Version 1.4	Revision Date: 09.04.2021		OS Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
Tox icity	icity to fish (Chronic tox-	:	NOEC: 0.084 mg Exposure time: 32 Species: Pimepha Method: OECD T	2 d ales promelas (fathead minnow)
aqu	icity to daphnia and other atic invertebrates (Chron- oxicity)	:	NOEC: 0.078 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211	
	actor (Chronic aquatic city)	:	1	
12.2 Per	sistence and degradabil	ity		
<u>Co</u>	nponents:			
Мо	ntelukast:			
Bio	degradability	:	Result: not rapidly Biodegradation: Exposure time: 28	0 %
Sta	bility in water	:	Hydrolysis: 50 %(	21.7 h)
Lor	atadine:			
	degradability	:	Result: not rapidly Biodegradation: Exposure time: 20 Method: OECD T	50 %
Sta	bility in water	:	Degradation half	life (DT50): 283 d
12.3 Bio	accumulative potential			
<u>Co</u>	nponents:			
Par	ntelukast: tition coefficient: n- anol/water	:	log Pow: > 4.3	
Par	atadine: tition coefficient: n- anol/water	:	log Pow: 2.35	
12.4 Mo	bility in soil			
<u>Co</u>	nponents:			
Dist	atadine: ribution among environ- ntal compartments	:	log Koc: 5.25 Method: OECD T	est Guideline 106



according to Regulation (EC) No. 1907/2006

Version 1.4	Revision Date: 09.04.2021		DS Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019	
12.5 Resu	Ilts of PBT and vPvB a	isse	ssment		
Prod	uct:				
	ssment				
12.6 Othe	r adverse effects				
Prod	uct:				
Endo tial	crine disrupting poten-	:	ered to have e REACH Article	e/mixture does not contain components consid- endocrine disrupting properties according to e 57(f) or Commission Delegated regulation 00 or Commission Regulation (EU) 2018/605 at or higher.	
SECTION	N 13: Disposal consi	der	ations		
13.1 Wast	te treatment methods				
Produ	uct aminated packaging	:	<ul> <li>Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.</li> <li>Empty containers should be taken to an approved waste ha dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.</li> </ul>		
SECTION	N 14: Transport infor	ma	tion		
14.1 UN n	umber				
ADN		:	UN 3077		
ADR		:	UN 3077		
RID		:	UN 3077		
IMDO	3	:	: UN 3077		
ΙΑΤΑ		:	: UN 3077		
14.2 UN p	oroper shipping name				
ADN		:	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLII N.O.S. (Loratadine)		
ADR			ENVIRONME	NTALLY HAZARDOUS SUBSTANCE, SOLID,	

according to Regulation (EC) No. 1907/2006



# Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021		0S Number: 79028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
IMDG		:	ENVIRONMENT/ N.O.S. (Loratadine)	ALLY HAZARDOUS SUBSTANCE, SOLID,
ΙΑΤΑ		:	Environmentally h (Loratadine)	nazardous substance, solid, n.o.s.
14.3 Trans	port hazard class(es)			
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDG		:	9	
ΙΑΤΑ		:	9	
14.4 Packir	ng group			
Classif	g group ication Code d Identification Number	:	III M7 90 9	
Classif Hazaro Labels	g group ication Code d Identification Number I restriction code	:	III M7 90 9 (-)	
Classif	g group ication Code d Identification Number	:	III M7 90 9	
<b>IMDG</b> Packin Labels EmS C		:	III 9 F-A, S-F	
	Cargo) g instruction (cargo	:	956	
Packin	g instruction (LQ) g group	: : :	Y956 III Miscellaneous	
Packin ger air		:	956	
	g instruction (LQ) g group	:	Y956 III Miscellaneous	

### 14.5 Environmental hazards

according to Regulation (EC) No. 1907/2006



## Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021	SDS Number: 4579028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
AD	M		
	rironmentally hazardous	: yes	
<b>AD</b> Env	<b>R</b> rironmentally hazardous	: yes	
<b>RID</b> Env	ironmentally hazardous	: yes	
<b>IMC</b> Mar	<b>)G</b> ine pollutant	: yes	
	A (Passenger)	: yes	
	A (Cargo) rironmentally hazardous	: yes	

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

: Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

		Quantity 1	Quantity 2
E2	ENVIRONMENTAL	200 t	500 t
	HAZARDS		

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

according to Regulation (EC) No. 1907/2006



## Loratadine / Montelukast Formulation

Version 1.4	Revision Date: 09.04.2021	SDS Number: 4579028-00005	Date of last issue: 10.10.2020 Date of first issue: 08.07.2019
The	components of this p	roduct are reported	in the following inventories:
AICS	6	: not determined	t de la constante de
DSL		: not determined	t
IECS	SC	: not determined	b
A Chemic	mical safety assessm al Safety Assessment N 16: Other informa	has not been carried	out.
Othe	r information		hanges have been made to the previous version I in the body of this document by two vertical
Full	text of H-Statements		
H319	)	: Causes seriou	s eye irritation.
H361			damaging fertility.
H400		: Very toxic to a	
H410	)	: very toxic to a	quatic life with long lasting effects.
Full	text of other abbrevia	tions	
	tic Acute		ute) aquatic hazard
	atic Chronic		ronic) aquatic hazard
Eye l Repr		: Eye irritation : Reproductive	tovicity
GB E			L - Workplace Exposure Limits
	EH40 / TWA		osure limit (8-hour TWA reference period)
GB E	H40 / STEL		oosure limit (15-minute reference period)
Wate Good	erways; ADR - Europe ds by Road; AIIC - Aus	ean Agreement conc tralian Inventory of In	rnational Carriage of Dangerous Goods by Inland erning the International Carriage of Dangerous dustrial Chemicals; ASTM - American Society for - Classification Labelling Packaging Regulation;

the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of



# Loratadine / Montelukast Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
1.4	09.04.2021	4579028-00005	Date of first issue: 08.07.2019

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Classification of the mixture	):	Classification procedure:
Sources of key data used to compile the Safety Data Sheet	•	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixtur	Classification proced	
Repr. 2	H361f	Calculation method
Aquatic Chronic 2	H411	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN